Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-95804306 in Relapsed or Refractory Hematological Malignancies
NCT07572006Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of JNJ-95804306 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL) and 3 more (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events by Severity. Started May 2026; status: recruiting.
02
Drugs
JNJ-95804306
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07572006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572006.